DC vaccines that were transfected with personalized tumor-associated antigen mRNA triggered specific CD4+ and CD8+ T cell responses in patients with advanced lung cancer or glioblastoma multiforme (GBM), and these responses were associated with favorable overall survival without significant autoimmune side effects (115). The gene discussed is CD4; the disease is glioblastoma.